Cookies on this website
We use cookies to ensure that we give you the best experience on our website. If you click 'Continue' we'll assume that you are happy to receive all cookies and you won't see this message again. Click 'Find out more' for information on how to change your cookie settings.

Many congratulations to Robert Watson, a NIHR Academic Clinical Fellow in the laboratory of Benjamin Fairfax in the Department of Oncology. Robert was successful in his application for a CRUK pre-doctoral research bursary.

Pre-doctoral research bursaries are awarded biannually by Cancer Research UK to "provide short-term funding to allow clinicians and other health professionals to get involved in research projects early in their career". This scheme was ideal for Robert Watson, a junior doctor with an interest in academic research. He is currently taking a year out from his clinical training to conduct research in the laboratory of Benjamin Fairfax at the MRC WIMM, and is interested in applying for a PhD at a later date. "This CRUK grant will support my research this year" explains Rob "It will give me a chance to experience research and develop my skills, and hopefully gather preliminary data that will help me apply for a PhD".

The laboratory of Dr Benjamin Fairfax is examining the genetic changes that accompany the treatment of cancer with immunotherapies. During his time in the lab, Robert will be using sequencing techniques to investigate changes to the T cell repertoire during checkpoint inhibitor treatments. "I am very keen to work in the area of immunoncology and to further develop my skills in genetic medicine and computational biology, so this projects fits well with the lab's strategy and my own personal aims", says Robert. The successful bid will provide £25,000 towards the project's research expenses.

Similar stories

Time-varying nature of clinical risk factors for pancreatic cancer may aid earlier diagnosis

Body mass index, blood tests, comorbidities and medication use are temporally associated with cancer risk in the three years before a pancreatic cancer diagnosis.

Population-scale study highlights ongoing risk of COVID-19 in some cancer patients despite vaccination

COVID-19 vaccination is effective in most cancer patients, but the level of protection against COVID-19 infection, hospitalisation and death offered by the vaccine is less than in the general population and vaccine effectiveness wanes more quickly.

OUH agrees long COVID research collaboration with Polarean

The collaboration will look at understanding the long-term effects of COVID-19 through cutting-edge MRI analysis.

Lung abnormalities found in long COVID patients with breathlessness

Researchers have identified abnormalities in the lungs of long COVID patients who are experiencing breathlessness that cannot be detected with routine tests.

New blood-based test is the first ever to simultaneously identify if a patient has cancer and if it has spread

A publication by University of Oxford researchers describes a new minimally invasive and inexpensive blood test that can identify cancer in patients with non-specific symptoms. The early success of this technology makes it the first blood-based test that not only detects cancer in this population but can simultaneously identify if a cancer has spread.